Celon Labs-Aurobindo tieup to develop oncology products

Tags: News

Market for cancer drugs pegged by 2018 at $100 billion

Sequoia Capital-backed Celon Labs has joined hands with pharma major Aurobindo to make and sell innovative and niche hormonal and oncology products, it said on Monday. These generic formulations will be marketed in the US and Europe under a special purpose vehicle named ‘Eugia Pharma Specialities’

Aurobindo Pharma owns 60 per cent in the SPV and the rest is with Celon.

“Both the companies will be making significant investments towards this joint venture, including Celon transferring one of its upcoming hormonal manufacturing facilities at Hyderabad. This would enable to file or submit products for the US and other markets from 2014 onwards,” the company said in a statement.

Estimates suggest that it could be a $100 billion market for oncology drugs alone by 2018.

“The joint venture brings both companies one step closer in developing high quality, complex injectable hormonal and oncology products and also support their strategy to enter key regulated markets including US and Europe,” said Vijay Vasireddy, chief executive officer.

Celon Labs has a product portfolio that caters the niche therapy segment in areas like oncology, critical care and gynecology. Like in Celon, Aurobindo had made strategic acquisitions and investments into Silicon Labs to maintain supplies of Penem non-sterile APIs along with Hyacinths Pharma, earlier this year.

Meanwhile, by 2015 financial year Celon Labs was targeting to achieve a turnover of Rs 450 crore.

trushnaudgirkar@mydigitalfc.com

Post new comment

E-mail ID will not be published
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

EDITORIAL OF THE DAY

  • Amit Shah deserved to be crowned President of India, some say

    The Bharatiya Janata Party is now firmly in the hands of Modi’s alter ego, which in plain English means ‘another side of oneself, a second self’

FC NEWSLETTER

Stay informed on our latest news!

INTERVIEWS

GV Nageswara Rao

MD & CEO, IDBI Federal Life

Timothy Moe

Goldman Sachs

Chander Mohan Sethi

CMD, Reckitt Benckiser India

COLUMNIST

Arun Nigavekar

Necessary yet inadequate boost to education

The finance minister, in the very first minutes of his ...

Zehra Naqvi

We must overcome the fear of death

It is the biggest irony that the only thing that’s ...

Dharmendra Khandal

Jawai leopards and locals can coexist peacefully

At first glance, the Jawai landscape seems like a large ...

INTERVIEWS

William D. Green

Chairman & CEO, Accenture